Abstract
The introduction of recombinant human erythropoietin (rHuEPO) has proven to be a major advance in the therapeutic options available for managing anemia in cancer patients. The results of placebo-controlled clinical trials and large, community-based, open-label studies have confirmed that epoetin alfa, a recombinant human erythropoietin, significantly reduces transfusion requirements, and reliably increases hemoglobin (Hb) levels in anemic (Hb level
Original language | English |
---|---|
Pages (from-to) | 22-32 |
Number of pages | 10 |
Journal | Oncology |
Volume | 68 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2005 |
Keywords
- Anemia
- Cancer
- Epoetin alfa
- Fatigue
- Quality of life